MedTrace Logo

ZD6474 Phase IIa Dose Finding Multicentre Study

NCT00252746 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2016-08-25

No results posted yet for this study

Summary

To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively

Conditions

  • Non Small Cell Lung Carcinoma

Interventions

DRUG

ZD6474 (vandetanib) 100mg

once daily oral dose

DRUG

ZD6474 (vandetanib) 200mg

once daily oral dose

DRUG

ZD6474 (vandetanib) 300mg

once daily oral dose

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252746 on ClinicalTrials.gov